Alpine Woods Capital Investors’s Amicus Therapeutics FOLD Stock Holding History

Alpine Woods Capital Investors’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,000	Closed	-$462K	–	235
2020 Q4	$462K	Hold	20,000	–	–	0.06%	183
2020 Q3	$282K	Hold	20,000	–	–	0.04%	213
2020 Q2	$302K	Hold	20,000	–	–	0.06%	215
2020 Q1	$185K	Buy	+20,000	New	+$190K	0.04%	239

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alpine Woods Capital Investors's FOLD Position: Q1 2021 in Review

Alpine Woods Capital Investors sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 20,000 shares — an estimated $462K sold.

Alpine Woods Capital Investors first reported a position in FOLD in Q1 2020 and held it in 4 quarters. The position peaked at $462K in Q4 2020. 259 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

Alpine Woods Capital Investors reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
Alpine Woods Capital Investors sold 20,000 Amicus Therapeutics shares in Q1 2021, an estimated $462K.
Alpine Woods Capital Investors first reported a position in Amicus Therapeutics in Q1 2020 and held it in 4 quarters.
Alpine Woods Capital Investors's Amicus Therapeutics position peaked at $462K in Q4 2020.
259 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Alpine Woods Capital Investors's 13F filing for Q1 2021, filed 11 May 2021.